skip to main content
UK Health Security Agency

Wilms' Tumor 17.94

Wilms' Tumor 17.94

Catalogue No.

17100502

Cell Line Name

Wilms' Tumor 17.94

Cell Line Description

The Wilms' Tumor 17.94 cell line is an anaplastic Wilms' Tumor (WT) cell line, which expressed NCAM, SALL1, and phenotypic features expected of metanephric blastema-derived cells. In Brown et al., (2005) treatment of 17.94 cells with 12-O-Tetradecanoylphorbol 13-acetate caused morphological changes, which led to reduced NCAM and SALL1 expression, but expression of vimentin was maintained. Wilms' Tumor 17.94 cell line contains a TP53 mutation but lacks mutations in WT1, WTX, or CTNNB1, other genes involved in WT pathogenesis.

General Info

Species

Human

Unique to ECACC

Yes

Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.

Characteristics

Receptors

Expresses NCAM, SALL1, and CITED1-phenotypic features expected of metanephric blastema-derived cells

Products

Forms tumours in athymic nude mice.

Tissue of Origin

Kidney

Morphology

Epithelial

DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 11,12
D3S1358: 16
D5S818: 11
D7S820: 9,11
D8S1179: 10,13
D13S317: 8
D16S539: 11
D18S51: 14,17
D21S11: 29
FGA: 22,23
Penta D: 9,11
Penta E: 7,11
TH01: 8,9.3
TPOX: 8
vWA: 14,16

Karyotype

The cells demonstrate no loss of heterozygosity at 7p, 11p, or 16q although DNA hypermethylation was detected at several loci, including the H19 differentially methylated region and at the PCDH@ gene clusters at 5q31.

Applications

The derivation of the 17.94 cell line should help to further dissect the genetic-epigenetic interactions involved in the pathogenesis of WT.

Disease

Nephroblastoma

Culture Conditions

Cell Type

Epithelial

Subculture Routine

Subculture semi-confluent cultures 1: 2 once a week using TrypLE Express™ Seed between 2-4 x 10⁴ cells/cm². Culture at 37°C with 5% CO₂. Freeze medium: 70% medium, 20% FBS, 10% DMSO

Culture Medium

Dulbecco's Modified Eagles Medium (80%) with 20% heat - inactivated FBS

Growth Mode

Adherent

Additional Info

Depositor

Ximbio (formerly known as Cancer Research Technologies Limited)

Country of Origin

United Kingdom

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Brown KW1, Charles A, Dallosso A, White G, Charlet J, Standen GR, Malik K. Characterization of 17.94, a novel anaplastic Wilms' tumor cell line. Cancer Genet. 2012 Jun;205(6):319-26. doi: 10.1016/j.cancergen.2012.04.009.

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: Wilms' Tumor 17.94 (ECACC 17100502).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.